Smulders Y M, Rakic M, Stehouwer C D, Weijers R N, Slaats E H, Silberbusch J
Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
Diabetes Care. 1997 Jun;20(6):999-1005. doi: 10.2337/diacare.20.6.999.
To assess the degree of interindividual variation in the rate of progression of microalbuminuria and to identify determinants of progression of microalbuminuria in patients with NIDDM.
In a prospective cohort study, 58 microalbuminuric NIDDM patients were followed for a period of at least 24 months. During this period, the level of microalbuminuria in these patients was assessed in triplicate 24-h urine samples on at least four separate visits. All patients had stable metabolic control and controlled blood pressure during follow-up. Microalbuminuria was defined as an albumin-to-creatinine ratio in 24-h urine of between 3 and 30 mg/mmol. The individual rates of progression of microalbuminuria were calculated from linear regression analysis. At baseline, the following data were collected for all patients: age, sex, ethnicity, time since diagnosis of NIDDM, smoking habits, drug use, blood pressure, BMI, HbA1c, serum creatinine, cholesterol, triglyceride, and HDL cholesterol concentrations.
Microalbuminuria was found to progress linearly in time. Considerable differences in rates of progression of microalbuminuria were found, the absolute yearly change in albumin-to-creatinine ratio ranging from -5.2 to 12.9 mg/mmol. In bivariate analyses, serum triglyceride concentration, use of ACE inhibitors, mean arterial blood pressure, HDL cholesterol, and time since diagnosis of NIDDM correlated with progression of microalbuminuria (P < or = 0.05). In stepwise multiple regression analysis, a high triglyceride-to-HDL cholesterol ratio at baseline (P = 0.006) and the use of ACE inhibitors (P = 0.007) were identified as the only independent predictors of progression of microalbuminuria.
The rate of progression of microalbuminuria in NIDDM differs considerably between subjects. Diabetic dyslipidemia (high serum triglyceride and low HDL cholesterol) is a predictor of more rapid progression of microalbuminuria in patients with well-controlled blood pressure.
评估非胰岛素依赖型糖尿病(NIDDM)患者微量白蛋白尿进展速率的个体间差异程度,并确定微量白蛋白尿进展的决定因素。
在一项前瞻性队列研究中,对58例微量白蛋白尿的NIDDM患者进行了至少24个月的随访。在此期间,至少在四次单独就诊时,对这些患者的24小时尿样进行三次微量白蛋白尿水平评估。所有患者在随访期间代谢控制稳定且血压得到控制。微量白蛋白尿定义为24小时尿中白蛋白与肌酐比值在3至30mg/mmol之间。微量白蛋白尿的个体进展速率通过线性回归分析计算得出。在基线时,收集了所有患者的以下数据:年龄、性别、种族、NIDDM诊断后的时间、吸烟习惯、药物使用情况、血压、体重指数(BMI)、糖化血红蛋白(HbA1c)、血清肌酐、胆固醇、甘油三酯和高密度脂蛋白胆固醇浓度。
发现微量白蛋白尿随时间呈线性进展。微量白蛋白尿进展速率存在显著差异,白蛋白与肌酐比值的绝对年变化范围为-5.2至12.9mg/mmol。在双变量分析中,血清甘油三酯浓度、血管紧张素转换酶(ACE)抑制剂的使用、平均动脉血压、高密度脂蛋白胆固醇以及NIDDM诊断后的时间与微量白蛋白尿的进展相关(P≤0.05)。在逐步多元回归分析中,基线时高甘油三酯与高密度脂蛋白胆固醇比值(P = 0.006)和ACE抑制剂的使用(P = 0.007)被确定为微量白蛋白尿进展的唯一独立预测因素。
NIDDM患者微量白蛋白尿的进展速率在个体间差异很大。糖尿病血脂异常(高血清甘油三酯和低高密度脂蛋白胆固醇)是血压控制良好的患者微量白蛋白尿进展更快的预测因素。